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Breast cancer is the most common malignancy and the
second cause of cancer mortality in women. Despite tre-
mendous progress, with 80% overall survival at 10 years,
the outcomes of the disease are extremely heteroge-
neous and it is very hard to predict prognosis and
response to therapy. This clinical behaviour reflects the
underlying heterogeneity of breast cancers and the char-
acterization of these at the molecular level is the first
step towards truly individualized cancer management.
We have now profiled over 2000 breast cancers with
linked clinical outcome data at the genomic, transcrip-
tomic and epigenomic level. This constitutes the largest
“omic” dataset ever gathered in human cancer and the
molecular landscapes obtained provide unique insights
into the biology and clinical behaviour of breast cancer.
Our laboratory is now exploring the potential transla-
tion of this knowledge into better prognostic and pre-
dictive markers, and in parallel is studying its functional
significance at the cellular and organism level with the
aim of unravelling the mechanisms of mammary gland
malignant transformation.
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